Cerulean Announces Promotion of Scott Eliasof, PhD to Senior Vice President and Chief Scientific Officer
October 26 2016 - 7:00AM
Business Wire
Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company
developing nanoparticle-drug conjugates (NDCs), today announced
that Scott Eliasof, PhD, has been promoted to the role of Senior
Vice President and Chief Scientific Officer, effective immediately.
Dr. Eliasof joined Cerulean in 2007 and was appointed Vice
President of Research in 2011.
“For the past ten years, Scott has been one of the driving
forces behind our NDC innovations, and we are pleased to expand his
role at this critical time for our Company,” said Christopher D. T.
Guiffre, President and Chief Executive Officer of Cerulean. “Our
versatile NDC platform created our proprietary pipeline, including
CRLX101 and CRLX301, and enabled our recently-announced
collaboration with Novartis, which includes potential milestone
payments for up to five targets. We look forward to Scott’s
leadership and continued contributions as we advance this pipeline
and platform.”
Before joining Cerulean in 2007, Dr. Eliasof was the director of
the Chemical Biology Platform at the Broad Institute, directing a
multi-disciplinary team of professional scientists and technicians
in the fields of synthetic chemistry, analytical chemistry,
high-throughput screening, computational science, and software
engineering. This interdisciplinary organization is closely
affiliated with the laboratory of Stuart Schreiber from Harvard
University and is one of the largest and oldest academic screening
centers in the country. Prior to joining the Broad Institute, Dr.
Eliasof worked at Millennium Pharmaceuticals, where he managed
scientific teams in cellular biology, molecular biology,
neuroscience, and bioinformatics for a large-scale genomics-based
drug discovery program. Earlier in his career, Dr. Eliasof was at
Neurocrine Biosciences, where he played a key role in the
exploration of glutamate transporters in the field of stroke and
neurological disorders. Dr. Eliasof earned his B.S. from MIT in
electrical engineering, Ph.D. from the University of California at
Berkeley in neuroscience, and completed his post-doctoral
fellowship at the Vollum Institute in Portland, Oregon.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people
living with cancer. We apply our Dynamic Tumor Targeting™ Platform
to create a portfolio of NDCs designed to selectively attack tumor
cells, reduce toxicity by sparing the body's normal cells, and
enable therapeutic combinations. Our first platform-generated NDC
clinical candidate, CRLX101, is in multiple clinical trials in
combination with other cancer treatments, all of which aim to
unlock the power of combination therapy. Our second
platform-generated NDC clinical candidate, CRLX301, is in a Phase
1/2a clinical trial. For more information, please visit
http://www.ceruleanrx.com/.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements about the
clinical development of our product candidates, statements about
the sufficiency of our cash and cash equivalents to fund our
operations, debt service and other scheduled expenditures and other
statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "hypothesize," "intend,"
"may," "plan," "potential," "predict," "project," "should,"
"target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties inherent in the initiation and completion of clinical
trials, availability and timing of data from ongoing and future
clinical trials and the results of such trials, whether preliminary
results from a clinical trial will be predictive of the final
results of that trial or whether results of early clinical trials
will be indicative of the results of later clinical trials,
expectations for regulatory approvals, availability of funding
sufficient for our foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the "Risk Factors" section of our Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on August 4,
2016, and in other filings that we make with the Securities and
Exchange Commission. In addition, any forward-looking statements
included in this press release represent our views only as of the
date of this release and should not be relied upon as representing
our views as of any subsequent date. We specifically disclaim any
obligation to update any forward-looking statements included in
this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161026005275/en/
Cerulean Pharma Inc.Nicole P. Jones, 781-209-6385Director,
Investor Relations and Corporate
Communicationsnjones@ceruleanrx.comorArgot PartnersSusan Kim,
212-600-1902
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2024 to May 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From May 2023 to May 2024